Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ovarian Neoplasms

Free Subscription 08.07.2019 1 Am J Obstet Gynecol 2 BMC Cancer 1 Cancer Res 4 Gynecol Oncol 1 Int J Cancer 1 J Clin Oncol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Obstet Gynecol

1. GEMER O, Segev Y, Helpman L, Hag-Yahia N, et al
   Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group study.
   Am J Obstet Gynecol. 2018 May 21. pii: S0002-9378(18)30408.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

2. LIU B, Huang X, Li Y, Liao W, et al
   JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
   BMC Cancer. 2019;19:645.
   PubMed     Text format     Abstract available
   
   
3. PARADISO AV, Digennaro M, Patruno M, De Summa S, et al
   BRCA germline mutation test for all woman with ovarian cancer?
   BMC Cancer. 2019;19:641.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

4. TESFAY L, Paul BT, Konstorum A, Deng Z, et al
   Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death.
   Cancer Res. 2019 Jul 3. pii: 0008-5472.CAN-19-0369.
   PubMed     Text format     Abstract available
   
   

   
   Gynecol Oncol

5. MORSE CB, Toukatly MN, Kilgore MR, Agnew KJ, et al
   Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
   Gynecol Oncol. 2019 Feb 22. pii: S0090-8258(19)30121.
   PubMed     Text format     Abstract available
   
   
6. MESQUITA KA, Alabdullah M, Griffin M, Toss MS, et al
   ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
   Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30124.
   PubMed     Text format     Abstract available
   
   
7. MURAKAMI R, Matsumura N, Michimae H, Tanabe H, et al
   The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology G
   Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30120.
   PubMed     Text format     Abstract available
   
   
8. KRASNER CN, Castro C, Penson RT, Roche M, et al
   Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Mullerian origin.
   Gynecol Oncol. 2019;153:223-229.
   PubMed     Text format     Abstract available
   
   

   
   Int J Cancer

9. ZHU Q, Zhang J, Chen Y, Hu Q, et al
   Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.
   Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.
   PubMed     Text format     Abstract available
   
   

   
   J Clin Oncol

10. KOOLE SN, van Lieshout C, van Driel WJ, van Schagen E, et al
    Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
    J Clin Oncol. 2019 Jun 28:JCO1900594. doi: 10.1200/JCO.19.00594.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: